Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Live
Q1 2014 The Medicines Company Earnings Conference Call
04/23/14 at 8:30 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at Barclays Healthcare Conference
03/12/14 at 1:00 p.m. ET
2014 Guidance Worksheet
The Medicines Company at JPMorgan Healthcare Conference
The Medicines Company Analyst Meeting
The Medicines Company Analyst Meeting Presentation
The Medicines Company Analyst Meeting Agenda
Click here for the Oritavancin Program Results.pdf
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$24.55
Change (%) Stock is Down 0.35 (1.41%)
Volume1,315,278
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/09/14The Medicines Company to Announce First Quarter 2014 Financial Results on Wednesday, April 23, 2014
Conference Call to Be Held at 8:30 a.m. Eastern Time PARSIPPANY, NJ -- (Marketwired) -- 04/09/14 -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 23 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results, operational developments, and outlook for 2014. The conference call will be available via phone and webcast. The dial-in information is listed below: Domestic Dial In: + 1 877-359-9508 International Dial ... 
Printer Friendly Version
04/03/14FDA Accepts the Filing of The Medicines Company's US Biologic License Application for Fibrocaps Hemostatic Agent
PARSIPPANY, NJ -- (Marketwired) -- 04/03/14 -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date (PDUFA date)... 
Printer Friendly Version
03/31/14Update on Angiomax® (Bivalirudin) Patent Litigation
PARSIPPANY, NJ -- (Marketwired) -- 03/31/14 -- The Medicines Company (NASDAQ: MDCO) -- On March 31, 2014, Judge Andrews in the U.S. District Court of Delaware issued his Trial Opinion in The Medicines Company v. Hospira, Inc. The case involves Hospira's Abbreviated New Drug Applications ("ANDAs") seeking approval to commercially manufacture, use or sell a generic version of The Medicines Company's Angiomax® bivalirudin drug product before the expiration of the patents covering this product. The... 
Printer Friendly Version
03/30/14Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax® (Bivalirudin) Presented at ACC.14
New Pooled Analysis of 5,800 Patients Shows Bivalirudin Associated With Reductions in Cardiac Death, Major Bleeding, Transfusion and NACE in STEMI Patients Undergoing PCI; Results Consistent With Previous Results From HORIZONS-AMI and EUROMAX WASHINGTON, DC -- (Marketwired) -- 03/30/14 -- The Medicines Company (NASDAQ: MDCO) today reported a presentation of a pooled analysis of 5,800 patients in the EUROMAX and HORIZONS-AMI trials, two international clinical trials comparing Angiomax® (bivaliru... 
Printer Friendly Version
Upcoming Events
DateTitle
04/23/14 8:30 a.m. ET
Q1 2014 The Medicines Company Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.